Lessons From a Multi site International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120.

Authors :: Cleghorn, Farley
Pape, Jean W.
Schechter, Mauro
Bartholomew, Courtenay
Sanchez, Jorge
Jack, Noreen
Metch, Barbara J.
Hansen, Marianne
Allen, Mary
Huyen Cao
Montefiori, David C.
Tomaras, Georgia D.
Gurunathan, Sanjay
Eastman, Donna J.
Do Lago, Regina F.
Jean, Sonic
Lama, Javier R.
Lawrence, Dale N.
Wright, Peter F.
Source :: JAIDS: Journal of Acquired Immune Deficiency Syndromes. 10/1/2007, Vol. 46 Issue 2, p222-230. 9p. 4 Charts, 1 Graph.
Publication Year :: 2007
Abstract: The article evaluates the safety and immunogenicity of a clade B-derived, live canarypox HIV vaccine, vCP1452. It reports on the first multicenter, international National Institutes of Allergy and Infectious Diseases-sponsored HIV vaccine trial in Brazil, Haiti, Peru and Trinidad. The vaccine was administered alone or with a heterologous boost of MN rgp120 glycoprotein.

Subjects :: *AIDS vaccines
*HIV infections
*VACCINATION
*PREVENTION of communicable diseases

Full Text Access

Tools